CDK2-IN-19

• UNSPSC Description:

  CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk2-in-19.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC(C=C(S(=O)(NC)=O)C=C1)=C1NC2=NC=C3C(N=C(C(N4C[C@@H](OC)[C@@H]4C)=O)C=C3)=N2.FC(C=C(S(=O)(NC)=O)C=C5)=C5NC6=NC=C7C(N=C(C(N8C[C@H](OC)[C@H]8C)=O)C=C7)=N6

• Molecular Weight:

  460.48

• References & Citations:

  [1]Mingshuo Zeng, et al. Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2). ACS Med. Chem. Lett. 2023.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported